Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 3;3(3):CD010503.
doi: 10.1002/14651858.CD010503.pub2.

Non-contraceptive Oestrogen-Containing Preparations for Controlling Symptoms of Premenstrual Syndrome

Affiliations
Free PMC article
Review

Non-contraceptive Oestrogen-Containing Preparations for Controlling Symptoms of Premenstrual Syndrome

Bushra Naheed et al. Cochrane Database Syst Rev. .
Free PMC article

Abstract

Background: Premenstrual syndrome (PMS) is a psychological and somatic disorder of unknown aetiology, with symptoms typically including irritability, depression, mood swings, bloating, breast tenderness and sleep disturbances. About 3% to 10% of women who experience these symptoms may also meet criteria for premenstrual dysphoric disorder (PMDD). PMS symptoms recur during the luteal phase of the menstrual cycle and reduce by the end of menstruation. PMS results from ovulation and may be due to ovarian steroid interactions relating to neurotransmitter dysfunction. Premenstrual disorders have a devastating effect on women, their families and their work.Several treatment options have been suggested for PMS, including pharmacological and surgical interventions. The treatments thought to be most effective tend to fall into one of two categories: suppressing ovulation or correcting a speculated neuroendocrine anomaly.Transdermal oestradiol by patch, gel or implant effectively stops ovulation and the cyclical hormonal changes which produce the cyclical symptoms. These preparations are normally used for hormone therapy and contain lower doses of oestrogen than found in oral contraceptive pills. A shortened seven-day course of a progestogen is required each month for endometrial protection but can reproduce premenstrual syndrome-type symptoms in these women.

Objectives: To determine the effectiveness and safety of non-contraceptive oestrogen-containing preparations in the management of PMS.

Search methods: On 14 March 2016, we searched the following databases: the Cochrane Gynaecology and Fertility Group (CGF) Specialised Register; Cochrane Central Register of Studies (CRSO); MEDLINE; Embase; PsycINFO; CINAHL; ClinicalTrials.gov; metaRegister of Controlled trials (mRCT); and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal. In addition, we checked the reference lists of articles retrieved.

Selection criteria: We included published and unpublished randomized placebo or active controlled trials on the efficacy of the use of non-contraceptive oestrogen-containing preparations in the management of premenstrual syndrome in women of reproductive age with PMS diagnosed by at least two prospective cycles without current psychiatric disorder.

Data collection and analysis: Two review authors independently selected studies, assessed risk of bias, extracted data on premenstrual symptoms and adverse effects and entered data into Review Manager 5 software. Where possible, intention-to-treat or modified intention-to-treat analysis was used. Studies were pooled using a fixed-effect model, analysing cross-over trials as parallel trials. Standardised mean differences (SMDs) with 95% confidence intervals (CIs) were calculated for premenstrual symptom scores. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes. The overall quality of the evidence was assessed using the GRADE working group methods.

Main results: The search resulted in 524 potentially relevant articles. Five eligible randomized controlled trials (RCTs) were identified (305 women). Trials using oral tablets, transdermal patches and implants were identified. No trial used gels.One small cross-over trial (11 women, effective sample size 22 women considering cross-over trials) compared oral luteal-phase oestrogen versus placebo. Data were very low quality and unsuitable for analysis, but study authors reported that the intervention was ineffective and might aggravate the symptoms of PMS. They also reported that there were no adverse events.Three studies compared continuous oestrogen with progestogen versus placebo (with or without progestogen). These trials were of reasonable quality, although with a high risk of attrition bias and an unclear risk of bias due to potential carry-over effects in two cross-over trials. Continuous oestrogen had a small to moderate positive effect on global symptom scores (SMD -0.34, 95% CI -0.59 to -0.10, P = 0.005, 3 RCTs, 158 women, effective sample size 267 women, I² = 63%, very low quality evidence). The evidence was too imprecise to determine if the groups differed in withdrawal rates due to adverse effects (RR 0.64, 95% CI 0.26 to 1.58, P = 0.33, 3 RCTs, 196 women, effective sample size 284 women, I² = 0%, very low quality evidence). Similarly, the evidence was very imprecise in measures of specific adverse events, with large uncertainties around the true value of the relative risk. None of the studies reported on long-term risks such as endometrial cancer or breast cancer.One study compared patch dosage (100 vs 200 µg oestrogen, with progestogen in both arms) and had a high risk of performance bias, detection bias and attrition bias. The study did not find evidence that dosage affects global symptoms but there was much uncertainty around the effect estimate (SMD -1.55, 95% CI -8.88 to 5.78, P = 0.68, 1 RCT, 98 women, very low quality evidence). The evidence on rates of withdrawal for adverse events was too imprecise to draw any conclusions (RR 0.70, 95% CI 0.34 to 1.46, P = 0.34, 1 RCT, 107 women, low-quality evidence). However, it appeared that the 100 µg dose might be associated with a lower overall risk of adverse events attributed to oestrogen (RR 0.51, 95% Cl 0.26 to 0.99, P = 0.05, 1 RCT, 107 women, very low quality evidence) with a large uncertainty around the effect estimate.The overall quality of the evidence for all comparisons was very low, mainly due to risk of bias (specifically attrition), imprecision, and statistical and clinical heterogeneity.

Authors' conclusions: We found very low quality evidence to support the effectiveness of continuous oestrogen (transdermal patches or subcutaneous implants) plus progestogen, with a small to moderate effect size. We found very low quality evidence from a study based on 11 women to suggest that luteal-phase oral unopposed oestrogen is probably ineffective and possibly detrimental for controlling the symptoms of PMS. A comparison between 200 µg and 100 µg doses of continuous oestrogen was inconclusive with regard to effectiveness, but suggested that the lower dose was less likely to cause side effects. Uncertainty remains regarding safety, as the identified studies were too small to provide definite answers. Moreover, no included trial addressed adverse effects that might occur beyond the typical trial duration of 2-8 months. This suggests the choice of oestrogen dose and mode of administration could be based on an individual woman's preference and modified according to the effectiveness and tolerability of the chosen regimen.

Conflict of interest statement

BN, JHK, OAU and FO have no interests to declare. PMSO has received some travel expenses, lecture fees and consultancy fees from Bayer Women’s Health, Abbvie Pharma, Umecrine Mood and Asarina Pharma for his work related to premenstrual disorders but on topics unrelated to the use of non‐contraceptive oestrogens in PMS.

Figures

Figure 1
Figure 1
Study flow diagram.
Figure 2
Figure 2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figure 3
Figure 3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figure 4
Figure 4
Forest plot of comparison: 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., outcome: 1.1 Symptom scores.
Figure 5
Figure 5
Forest plot of comparison: 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., outcome: 1.2 Withdrawal due to adverse events.
Analysis 1.1
Analysis 1.1
Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 1 Symptom scores.
Analysis 1.2
Analysis 1.2
Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 2 Withdrawal due to adverse events.
Analysis 1.3
Analysis 1.3
Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 3 Specific adverse events (E+P versus placebo).
Analysis 1.4
Analysis 1.4
Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 4 Specific symptoms of PMS: psychological.
Analysis 1.5
Analysis 1.5
Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 5 Specific symptoms of PMS: physical.
Analysis 1.6
Analysis 1.6
Comparison 1 Oestrogen in combination with progestogen (sequential or continuous) versus placebo., Outcome 6 Quality of life (E+P versus placebo).
Analysis 2.1
Analysis 2.1
Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 1 Symptoms score: maximum mean daily PDQ.
Analysis 2.2
Analysis 2.2
Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 2 Adverse events.
Analysis 2.3
Analysis 2.3
Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 3 Specific symptoms of PMS.
Analysis 2.4
Analysis 2.4
Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 4 VAS Sense of wellbeing.
Analysis 2.5
Analysis 2.5
Comparison 2 Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups, Outcome 5 Patient satisfaction.

Update of

  • Cochrane Database Syst Rev. doi: 10.1002/14651858.CD010503

Similar articles

See all similar articles

Cited by 3 articles

LinkOut - more resources

Feedback